AXIM BIOTECHNOLOGIES, INC.
AXIM BIOTECHNOLOGIES, INC. (AXIM): 39 pipeline candidates · 5 upcoming catalysts · ~0 mo cash runway · 1 clinical trial. Updated within the last hour.
BioSniper Score
5-factor signal · derived from public data
0.1 months
D/E -1.39 · 0% dilution
Lead: Phase 3
39 candidates
5 upcoming, next in ~744d
N/A
A transparent, data-derived signal for AXIM BIOTECHNOLOGIES, INC.across cash runway, pipeline maturity & breadth, catalyst momentum and clinical/regulatory footprint. Each factor traces to tracked public filings — not an investment recommendation.
Key Financials
Market Cap
$1.7M
Cash
$6K
Quarterly Burn
$262K
Runway
0.1 mo
Revenue
$17K
Cash Runway vs Catalysts
A catalyst falls after projected cash runway — potential financing / dilution risk before it hits.
Pipeline (39 candidates)
| Drug | Phase |
|---|---|
| Asparaginase Erwinia chrysanthemi | Phase 2 |
| Bleomycin Sulfate | Phase 3 |
| Blinatumomab | Phase 3 |
| Brentuximab Vedotin | Phase 3 |
| Calaspargase Pegol | Phase 3 |
| Cytarabine | Phase 3 |
| Dacarbazine | Phase 3 |
| Dasatinib | Phase 3 |
| Daunorubicin | Phase 3 |
| Daunorubicin Hydrochloride | Phase 3 |
Showing 10 of 39 candidates. Sign up for full pipeline.
Upcoming Catalysts (5)
Clinical data readout — efficacy/safety results are a high-impact catalyst.
68.6% historical Phase 3 primary-endpoint success rate (n=363)
Loss of exclusivity — patent/exclusivity expiry opens the door to generic or biosimilar competition that can erode revenue.
Loss of exclusivity — patent/exclusivity expiry opens the door to generic or biosimilar competition that can erode revenue.
Loss of exclusivity — patent/exclusivity expiry opens the door to generic or biosimilar competition that can erode revenue.
Loss of exclusivity — patent/exclusivity expiry opens the door to generic or biosimilar competition that can erode revenue.
Frequently asked questions
How many drug candidates are in AXIM BIOTECHNOLOGIES, INC.'s pipeline?
AXIM BIOTECHNOLOGIES, INC. (AXIM) has 39 pipeline candidates tracked by BioSniper across SEC filings and clinical trial registrations.
What is AXIM BIOTECHNOLOGIES, INC.'s lead drug candidate?
AXIM BIOTECHNOLOGIES, INC.'s most advanced tracked candidate is Asparaginase Erwinia chrysanthemi (Phase 2) for Recurrent B Acute Lymphoblastic Leukemia.
What is AXIM BIOTECHNOLOGIES, INC.'s next catalyst?
AXIM BIOTECHNOLOGIES, INC.'s next tracked catalyst is a Phase3_Topline event — "Phase 3 Topline: A Phase III Randomized Trial of Steroids + Tyrosine Kinase Inhibitor (TKI) Induction With Chemothera" — expected July 1, 2028.
What is AXIM BIOTECHNOLOGIES, INC.'s cash runway?
Based on its most recent reported cash balance and quarterly burn rate, AXIM BIOTECHNOLOGIES, INC. has approximately 0.1 months of cash runway.
What is AXIM BIOTECHNOLOGIES, INC.'s market capitalization?
AXIM BIOTECHNOLOGIES, INC.'s market capitalization is approximately $1.7M.
Get the full picture on AXIM BIOTECHNOLOGIES, INC.
Deep pipeline analysis, financial trends, AI-powered investment signals, and real-time catalyst alerts.